Want to see HBIO full AI Analyst Report?
HBIO Stock Chart & Stats
$0.40
-$0.02(-0.93%)
At close: 4:00 PM EST
$0.40
-$0.02(-0.93%)
Day’s Range― - ―
52-Week Range$3.75 - $9.39
Previous CloseN/A
Volume27.75K
Average Volume (3M)27.29K
Market Cap
$27.74M
Enterprise Value$64.09M
Total Cash (Recent Filing)$7.10M
Total Debt (Recent Filing)$44.12M
Price to Earnings (P/E)―
Beta2.19
Next Earnings
Jul 30, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.20
Shares Outstanding4,510,182
10 Day Avg. Volume21,999
30 Day Avg. Volume27,292
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.16
Price to Sales (P/S)0.34
P/FCF Ratio5.29
Enterprise Value/Market Cap2.31
Enterprise Value/Revenue0.75
Enterprise Value/Gross Profit1.31
Enterprise Value/Ebitda-34.27
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.38
Revenue Forecast (FY)$88.60M
Bulls Say, Bears Say
Bulls Say
Backlog And Product DemandAn expanding backlog and strong demand for new products underpin a revenue guide that exceeded consensus, signaling sustained order momentum.
Operational Efficiency And ERP BenefitsAdjusted EBITDA exceeded estimates as expense discipline, a new ERP system, and a healthier consumables sales mix improved operational leverage.
Revenue And MarginsRevenue beat consensus and gross margins improved due to broad sales execution and financial discipline, supporting upside to profitability.
Bears Say
Government Funding RiskContinuation of a government shutdown and delayed NIH funding could push revenue toward the lower end of guidance, creating external funding risk for sales.
Guidance And Forecast RiskSustained disruption in public research funding could force guidance revisions and pressure expected profitability and valuation.
Revenue Timing And VisibilityDelays in federal research funding may postpone recognition of backlog-driven sales into later reporting periods, reducing near-term revenue visibility.
Harvard Bioscience News
HBIO FAQ
What was Harvard Bioscience’s price range in the past 12 months?
Harvard Bioscience lowest stock price was $3.75 and its highest was $9.39 in the past 12 months.
What is Harvard Bioscience’s market cap?
Harvard Bioscience’s market cap is $27.74M.
When is Harvard Bioscience’s upcoming earnings report date?
Harvard Bioscience’s upcoming earnings report date is Jul 30, 2026 which is in 28 days.
How were Harvard Bioscience’s earnings last quarter?
Harvard Bioscience released its earnings results on May 12, 2026. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.62 by $0.29.
Is Harvard Bioscience overvalued?
According to Wall Street analysts Harvard Bioscience’s price is currently Overvalued.
Does Harvard Bioscience pay dividends?
Harvard Bioscience does not currently pay dividends.
What is Harvard Bioscience’s EPS estimate?
Harvard Bioscience’s EPS estimate is -0.21.
How many shares outstanding does Harvard Bioscience have?
Harvard Bioscience has 4,510,182 shares outstanding.
What happened to Harvard Bioscience’s price movement after its last earnings report?
Harvard Bioscience reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.62. Following the earnings report the stock price went down -20.906%.
Which hedge fund is a major shareholder of Harvard Bioscience?
Currently, no hedge funds are holding shares in HBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Harvard Bioscience
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through websites and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic laboratories. It primarily sells its products under the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS, Warner, DSI, Panlab, Hugo Sachs, and Buxco brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
HBIO Company Deck
HBIO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed but balanced picture: meaningful operational progress and product-led margin improvement (strong NPI momentum, gross margin expansion, pharma sales growth and on-track cost-savings initiatives) were contrasted with near-term revenue pressure, regional softness (Americas and APAC), flat adjusted EBITDA and cash-flow headwinds from inventory builds and financing costs. Management reaffirmed guidance and highlighted multi-year strategic drivers, but near-term financials remain modest.View all HBIO earnings summariesTechnical Analysis
1 Day
3 Days
1 Week
1 Month
Ownership Overview
63.85% Insiders
19.15% Mutual Funds
11.43% Other Institutional Investors
1.78% Public Companies and
Individual Investors











